UNITED LAB: Class 1 innovative drug UBT251 injection has completed Phase Ia clinical trials in healthy Chinese subjects
I'm PortAI, I can summarize articles.
United Lab's wholly-owned subsidiary, Federal Biotechnology, has completed Phase I clinical trials of the first-class innovative drug UBT251 injection in healthy subjects in China. The study results show that UBT251 injection has good safety and tolerability in healthy subjects, as well as linear pharmacokinetic characteristics. The study supports once-weekly injection dosing. Subjects experienced a significant weight loss after administration, showing a clear advantage over the placebo group
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments